Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Net Margin (2016 - 2025)

United Therapeutics' Net Margin history spans 17 years, with the latest figure at 46.1% for Q4 2025.

  • For Q4 2025, Net Margin rose 386003.0% year-over-year to 46.1%; the TTM value through Dec 2025 reached 41.94%, down 1408.0%, while the annual FY2025 figure was 41.94%, 40.0% up from the prior year.
  • Net Margin for Q4 2025 was 46.1% at United Therapeutics, up from 42.36% in the prior quarter.
  • Across five years, Net Margin topped out at 21710.0% in Q4 2023 and bottomed at 3813.92% in Q4 2024.
  • The 5-year median for Net Margin is 40.92% (2024), against an average of 929.2%.
  • The largest annual shift saw Net Margin surged 2168312bps in 2023 before it crashed -2552392bps in 2024.
  • A 5-year view of Net Margin shows it stood at 27.02% in 2021, then dropped by -1bps to 26.88% in 2022, then soared by 80676bps to 21710.0% in 2023, then plummeted by -118bps to 3813.92% in 2024, then skyrocketed by 101bps to 46.1% in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Net Margin are 46.1% (Q4 2025), 42.36% (Q3 2025), and 38.76% (Q2 2025).